Skip to main content

Cornell University

Jiang Lab

Welcome to the Jiang research group at Cornell University


An important challenge in many biomedical and engineering applications is the prevention of unwanted nonspecific biomolecular and microorganism attachment on surfaces. We pioneered the molecular understanding, design and development of functional zwitterionic materials. Since the early 2000s, we have proposed the concept of super-hydrophilic zwitterionic materials, provided a molecular-level understanding of non-fouling mechanisms and developed several new classes of zwitterionic materials, including poly(carboxybetaine), poly(sulfobetaine), poly(trimethylamine N-oxide), poly(zwitterionic phosphatidylserine), and glutamic acid (E) and lysine (K)-containing poly(peptides). We have demonstrated no capsule formation upon subcutaneous implantation in mice up to one year, expansion of hematopoietic stem and progenitor cells (HSPCs) without differentiation, no anti-coagulants needed for artificial lungs in sheep, no antibodies generated against zwitterionic polymers and long-lasting environmentally benign marine coatings. These highly biocompatible zwitterionic materials are excellent alternatives to widely used poly(ethylene glycol) (PEG) counterparts as PEG immunogenicity was found in COVID-19 vaccines. The work leads to startup three companies (ZWI Therapeutics, Taproot Medical and Imperion Coatings) and over 50 awarded patents on zwitterionic technologies. Largely resulting from his work, zwitterionic materials have been widely adopted for biomedical and engineering applications. At Cornell, we aim to (a) integrate immunology into our biomaterial and drug delivery research programs and (b) translate our biomaterials and drug delivery technologies into medical and engineering practice. More specifically, we focus on two areas

Biomaterials for regenerative & precious medicine: We are developing highly biocompatible materials, which are biologically inert, immunosuppressive or active, using both rational design and combinatorial screening. In collaborations with Weill Cornell Medicine and others, we are working on the controlled culture of iPSCs and cancer organoids along with capsule-free long-term implants and anticoagulant-free blood-contacting devices. In addition, we continue our efforts on anti-fouling marine coatings.

Drug delivery for cancer vaccines & neurological diseases: We are developing low- immunogenicity and targeted viral and non-viral carriers (e.g., lipid nanoparticles, extracellular vehicles, AAVs, protein conjugates and fusion proteins) for the delivery of mRNAs, DNAs, proteins and small molecules. In collaborations with Weill Cornell Medicine, Cornell Vet Medicine, and others, we are working on cancer and infectious disease vaccines along the treatments of several diseases such as cancer, neurological diseases and diabetes.

We take a unique holistic approach to our research at the interfaces of materials and biological sciences from fundamental principles to applications. Novel materials and drug carriers are designed, synthesized, tested, improved and applied for a wide range of applications all within our group. The nature of our highly interdisciplinary and collaborative research program enables us to strive towards understanding nature at all levels and to solve real-world challenging problems. Creative ideas and innovative technologies with high and broad impacts are always our emphasis.

Please click on the icons above or browse our “research” section to learn more about our lab’s work.

Group photo – April 2022


Weill Hall

Lab space: 132, 134, 138 and 140

Office: 131 and 139

Kimball Hall

Lab space: 390